Introduction and Objectives: Dwight D. Eisenhower Army Medical Center has been involved in Prostate Cancer Awareness Week (PCAW) screening during the period 1995 -2000. The purpose of this study is to review the results of screening in a self-selected population of military beneficiaries at our institution. Materials and Methods: Screening involving a brief urologic history, digital rectal examination (DRE) and serum prostatic specific antigen (PSA) measurement was offered to our screening population. Patients with an elevated PSA ( > 4.0 ng/ml) and/or a suspicious DRE were considered for transrectal ultrasonography with prostate needle biopsy (TRUS/PNB). Patient health records were reviewed retrospectively and analyzed to determine patient demographic characteristics, PSA distribution, DRE results and cancer detection rates. Results: A total of 455 screening visits were performed from 1995 to 2000, of which 426 visits were included for analysis. Mean age of the study population was 57.4 y (40 -83). Seventy-one percent of the patients reported prior PSA screening visits. Forty-four patients met indications for biopsy. A total of 30 TRUS/PNB were performed demonstrating presence of cancer in three patients for an overall cancer detection rate of 0.7%. Conclusions: Our study shows that the overall prostate cancer detection rate at our institution is lower than detection rates previously reported in the literature. Potential reasons for this finding may include that the subjects participating in PCAW screening tended to be younger than in other series and that a majority of them had already undergone prior screening. These findings suggest the need to modify prostate cancer screening recommendations and to improve prostate cancer screening efficacy.
Introduction
Despite massive efforts of education, research and early detection, prostate cancer remains a diagnostic and therapeutic dilemma as we transition into the twenty-first century. It is the most commonly diagnosed malignancy in men in the USA and is second to lung cancer for cancer-specific death rates. 1 In spite of the high prevalence of prostate cancer in autopsy studies, men have an approximately 9.5 -12.5% lifetime risk of developing clinically apparent disease and a 3 -4.5% chance of dying from it. 2 Arguably the most significant advancement in the prostate cancer arena has been the use of prostatespecific antigen (PSA) in all aspects of management from early detection to follow-up. Although PSA has been able to presumably detect cancers at an earlier stage where cure might be possible, decreased disease specific mortality due to early screening has not been proven in a well designed, prospective, randomized study. Currently, large-scale randomized studies such as the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial in the USA and the European Randomized Study of Screening for Prostate Cancer (ERSPC) are ongoing, however, definitive results are not expected for several more years. 3 -5 With the introduction of PSA in the mid1980s and its widespread use for early detection, we are now able to retrospectively review some of the results in this non-controlled natural experiment of PSA testing. One such potential database stems from the efforts of the American Cancer Society through its National Prostate Cancer Awareness programs where screening is offered to a large number of men in the general population. Our institution has been involved with this program over the past 5 y in an effort to promote prostate cancer awareness and to allow a screening opportunity for those interested. The purpose of this study is to review the results of PSA screening in a self-selected population of military beneficiaries at an equal access tertiary care center. We compare these findings with prostate cancer detection rates from studies performed shortly after the wide spread use of PSA as a screening tool in the early detection of prostate cancer.
Methods and materials
Each year the American Cancer Society sponsors National Prostate Cancer Awareness Month during which participating urology centers offer education and screening for men in the general population. Eisenhower Army Medical Center has been involved in this program for the past 6 y (1995 -2000) and has offered screening to men aged 50 -75 (aged 40 -75 for African-Americans or men with a first-degree relative with prostate cancer) during a 3-day period in the Fall. All patients who signed up for this event underwent screening even if they did not meet the advertised inclusion criteria. The event is promoted through newspaper and television advertisements, military retirement fairs, as well as signs and flyers throughout the hospital. During their visit, a brief urologic history including determination of the International Prostate Symptom Score (IPSS) and prior PSA screening was obtained, digital rectal examination (DRE) performed and blood drawn for serum PSA determination. Blood samples were obtained before performing the rectal examination and were analyzed using the Bayer Immuno-1 Magnetic Separation (1999 -2000) and the Abbott Axysm (1995 -1998) Assays. These assays are highly correlated and the normal range is the same for both tests. Patients with an elevated PSA ( > 4.0 ng/ml), a suspicious DRE or both were considered for transrectal ultrasonography and prostate needle biopsy (TRUS/ PNB). The patients' health records were reviewed retrospectively and analyzed to determine patient demographic characteristics, PSA and DRE distributions, and overall cancer detection rates. The Composite Health Care System (CHCS) database was accessed to document prior PSA screening values. Each patient screening visit was considered as a separate data point in the analysis. Screening visits by some patients who participated in the screening program multiple times during this period are counted individually.
Statistical method
Z-score analysis was performed to compare differences between our data and that of other previously published reports.
Results
During the 6 y of our institution's involvement in the Prostate Cancer Awareness program, a total of 392 men presented for evaluation. During the period of this study, a total of 455 screening visits were performed in these men (accounting for those patients who presented for screening more than once between 1995 and 2000). Twenty-nine patients were excluded from data analysis. Reasons for exclusion included: patients under the age of 40 (n ¼ 11), incomplete screening (n ¼ 11), patients with prior history of prostate cancer (n ¼ 5), and medical records not available for review (n ¼ 2). The mean age of the remaining patients was 57.4 y (s.d. ¼ 10.1, range 40 -83). The age and racial distributions are displayed in Table 1 . A total of 302 patients reported having prior PSA screening visits (71% of the study population). In the 40 -49-y-old group, 34% reported previous screening for prostate cancer with PSA. This increased to 73% in the 50 to 59-y-old group, 86% in the 60 to 69-y-old group and 96% in the 70 to 79-y-old group. The average PSA value from prior screening was 1.43 ng/dl.
A total of 424 IPSS questionnaires were completed. In 57% of these, patients reported an IPSS < 8, 28% had an IPSS between 8 and 15, and the remaining 15% had an IPSS > 15. Mean PSA for this study cohort was 1.46 ng/dl (s.d. ¼ 1.63, range 0.1 -14.3 ng/dl). Twenty-six patients (6.1%) were found to have a PSA > 4.0, 14 patients (3.3%) had a suspicious DRE and four patients (0.9%) had both an abnormal DRE and elevated PSA. Thirty of the 44 men meeting biopsy criteria underwent TRUS/ PNB. Fourteen patients did not undergo biopsy for the following reasons: patient decision (n ¼ 7), patient comorbidities (n ¼ 2), recent prostatitis (n ¼ 2), normal TRUS (n ¼ 2), and prior negative biopsy (n ¼ 1). Three of the 30 patients undergoing TRUS/PNB were diagnosed with adenocarcinoma for a positive biopsy rate of 10% and overall cancer detection rate of 0.7% per screening visit or 0.8% per patient screened. Arbitrarily excluding the 40 -49 y old group (lower risk of prostate cancer detection) the overall detection rate was 0.9%. A total of 181 patients (42%) had a PSA of less than 1.5 ng/dl on prior PSA screening. In this group, one patient was found to have an abnormal PSA the following year and another patient was found to have a suspicious DRE on subsequent examination. Biopsies in both cases were negative. 
Discussion
The most striking observation from the review of prostate cancer screening during Prostate Cancer Awareness Week is the low overall detection rate of prostate cancer in our cohort. Even if the 40 to 49-y-old age group is excluded from analysis, there is a statistically significant difference in the cancer detection rates between our study and those previously published reports from large screening data bases (P < 0.05; Table 2 ). 6 -10 Additionally, the percentage of patients with an elevated PSA or an abnormal DRE in our series was significantly lower than previously published studies (P < 0.05; Table 3 ). 6 -8,10 Several possible reasons may account for the observed discrepancy. The first is that we might be failing to detect cancer in patients who meet our biopsy criteria. Although random sextant biopsies certainly have the potential for missing cancers when compared to more extensive biopsy strategies, 11 our methodology for screening is not significantly different from previous screening studies. Additionally, all specimens are reviewed by board certified pathologists and undergo peer review and quality control.
Secondly, we might be missing cancers because our arbitrary cut-off of 4 ng/dl might be too high, especially in younger patients. Although a possibility, this PSA cutoff level does not account for the difference between our review and those from prior reports because the same cutoff was used. 6 -10 If we used the age specific cut-off ranges reported by Oesterling et al, 12 we would have needed additional biopsies in the younger patients which may have increased the cancer yield, and perhaps, we would have avoided recommending biopsies in older patients which, in this study, were all negative.
A third possibility for the observed discrepancy is that our population has a lower prevalence of prostate cancer than the general population. Although this would be difficult to prove, it seems unlikely as military beneficiaries reflect the wide diversity found in the USA. Our study actually had a larger proportion of African-American men in whom one might expect the incidence of prostate cancer to be higher. However, the average age of our study population was significantly lower than those of previous studies (P < 0.05), a factor which may contribute to lower prostate cancer detection rates. It is unknown if any difference in dietary or exercise factors in our study population might account for the difference in prostate cancer detection rates when compared to other studies.
The most compelling explanation of the discrepancy might be due to the high incidence of patients who had undergone prior screening. When compared with PSA testing prevalence data from a study of 33 028 health professionals, our population appears to have a significantly higher percentage of patients who have been previously screened. 13 Studies have shown that once a patient gets into an annual screening program, and is found to have a normal digital rectal examination and PSA, the chances of cancer detection on subsequent visits is significantly lower. 14 Furthermore, in a population that undergoes screening for a prevalent disease, the 'cull effect' is often observed where there is an initial rise in disease detection upon the introduction of a disease screening strategy which is followed by a return to the true baseline detection rate which more accurately reflects the true prevalence of the disease. 15 In most of the prior studies, PSA had been recently introduced into clinical practice and the majority of patients presented for their first PSA screening. These studies were conducted in the era where the observed annual incidence of prostate cancer was on the rise. Subsequently, since its peak in 1993, the annual prostate cancer incidence in the USA has declined dramatically along with an observed stage migration to earlier stages of disease being noted on screening visits. 1 Since screening at our institution was widely available before our data collection period, the observed results may reflect a period in the decline of the incidence curve and may be closer to the expected cancer detection rate in a population that has been heavily screened.
Because of the apparent low yield of PSA screening in the early detection of prostate cancer, critics of screening make a strong argument citing the high cost/benefit ratio of widespread prostate cancer screening. There is no doubt that PSA screening is expensive (especially if utilized for all men in the accepted age-range), and that negative biopsies are inconvenient and uncomfortable for the patient. Although studies have shown that screening for prostate cancer may be comparable to other malignancies in cost per quality of life year gained, 16 our goal should be to refine our PSA testing algorithms so as to maximize the sensitivity and specificity of screening modalities. This is currently being done with the advent of age-specific ranges, PSA density, PSA velocity, free/ total PSA ratios, complexed PSA and a host of other molecular markers. In our study we observed that a significant proportion of men who had been screened previously had low PSA values ( < 1.5 ng/dl) in the past. In this group, we found that only 1% of patients met criteria for prostate biopsy on subsequent yearly screening, and none had cancer. Perhaps, as suggested by some authors, the recommended screening interval could be extended and the age at which recommended screening stops could be decreased in patients with a history of low PSA values. 17 Hopefully, through more study and evaluation we will be able to accurately target screening at the population most likely to benefit and decrease our negative biopsy rate while increasing cancer detection. An additional potential benefit of this screening program is the detection of other urologic conditions. In our series, more that a third of the patients had an IPSS greater than 8. These encounters allowed the opportunity to counsel patients regarding further evaluation and potential treatments for these other urologic symptoms and conditions addressed at the time of prostate cancer screening.
Conclusion
The introduction of PSA as a tool for prostate cancer detection has been a mixed blessing and currently much confusion and controversy exist regarding its usage. Although the role of PSA screening in decreasing disease specific mortality from prostate cancer has not been proven in a randomized trial, there is extensive evidence that PSA screening has increased the percentage of patients being treated at earlier stages of disease. The expected and hoped for result of this screening strategy is that the mortality rates from prostate cancer will continue to decrease as they have over the past several years. Current efforts to screen for prostate cancer must continue to focus on finding methods to improve the sensitivity and specificity of testing in order to maximize cancer detection in patients who might derive benefit from treatment and diminish the number of negative biopsies. These goals are essential to bring prostate cancer screening to a place where it will be cost-effective and truly beneficial to an 'at risk' population. At Eisenhower Army Medical Center we will continue to monitor outcome data from Prostate Cancer Awareness Week in order to potentially develop prospective, randomized trials which will improve screening recommendations.
